Deep-dive: Hugel (145020 KS)
South Korea’s low-cost botox leader now expanding to the US
Hi! Welcome to a subscriber-only edition of Asian Century Stocks – a newsletter about Asian value stocks. For a complete list of all previous posts, check out the Table of Contents.
Disclaimer: I am not licensed or regulated by the Monetary Authority of Singapore, and I am not a financial adviser. This post is my personal opinion, provided for informational purposes only. It is not a recommendation or an offer to buy, sell, or hold any security, and it does not take into account your objectives, financial situation, or needs. Investing carries substantial risk, including total loss of capital — do your own research and consult a MAS-licensed adviser before investing. Any estimates or forward-looking figures are my own and rest on assumptions that may prove wrong. As of 20 September 2026, I do not hold a position in Hugel (145020 KS); this reflects my position on that date only and will not be updated. I will not buy or sell shares in Hugel; within seven days of publication. I receive no compensation from any company, broker, platform, fund, publication or product issuer mentioned; my revenue comes solely from reader subscriptions. I have not verified the positions or compensation of any third party named here — assume they may hold positions in the securities discussed. Published by Delante Media Pte Ltd.
On Tuesday, Meera Kapoor wrote about how GLP-1 drugs cause people's skin to become saggy – the effect that's now popularly known as "Ozempic face".
Two solutions are botulinum neurotoxin ("Botox") and dermal fillers. Botox is injected into the skin to reduce wrinkles. Such wrinkles include frown lines, forehead lines and so-called "crow's feet.
Meanwhile, dermal fillers add volume in areas previously occupied by fat and provide structural support.
